CHICAGO (Reuters) – Scientists at Johnson & Johnson on Friday refuted an assertion in a major medical journal that the adenovirus-based design of their COVID-19 vaccine, which is similar AstraZeneca’s, may explain why both have been linked to very rare brain blood clots in some vaccine recipients.
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the…
The U.S. health regulator has sent a warning letter to Cardinal Health after an inspection of its facility in Illinois showed that the company was…
UK-listed drugmaker Indivior plans to seek shareholder approval next month for a primary listing in the United States, the company said on Thursday, which would…
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and…
Sanofi’s first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent,…
West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to…
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
Bristol Myers Squibb reported a first-quarter loss on Thursday as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a small…
Indian drugmaker Glenmark Life Sciences posted its first drop in profit for six quarters on Thursday as its mainstay active pharmaceutical ingredients (API) business was…
AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, boosted by demand for its blockbuster drugs and steady sales from partnered medicines…
